We have evaluated the effects of
bryostatin 1 on growth of a highly malignant p53-null mouse mammary
tumor line, 4T1, and the mechanism by which
bryostatin 1 inhibits in vitro growth and in vivo development of
tumor and
metastases from the orthotopic site.
Bryostatin 1 at 20-400 nM concentrations inhibits growth of 4T1 cells by approximately 60% in two-day cultures. Inhibition of growth is associated with an increase in the number of cells undergoing apoptosis with concomitant elevation in the steady state levels of
bax protein and drop in bcl-2 levels. The cytotoxic effect of
bryostatin 1 on 4T1 cells occurs independently of p53, since there was no evidence of p53-mediated transcriptional activity in 4T1 cells following treatment with
bryostatin 1.4T1 cells respond in vivo to
bryostatin 1 therapy (75 microg/kg
body weight). Intraperitoneal administration of
bryostatin 1 inhibits both primary and secondary
tumor growth by approximately 50%. However, although
bryostatin 1 has a remarkable capacity to slow
tumor growth and progression, it is unable to completely eradicate
tumor growth and progression due to in vivo development of
tumor resistance to
bryostatin 1. Levels and cellular distribution of PKCalpha and delta do not correlate with the growth inhibitory effects of
bryostatin 1 on 4T1 cells; however, reduction in cytosolic PKCalpha and delta without associated increase in membrane compartment appear to correlate with
bryostatin-resistance. Our results suggest that the
therapeutic effects of
bryostatin 1 in our system do not involve alterations in levels and distribution of PKC but rather a direct upregulation of bax/ bcl-2 ratios that is independent of p53.